Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHA-022121 drug-drug interaction study with CYP probe cocktail in healthy adults
NL-OMON49587Active, not recruiting
- Sponsor
- Pharvaris
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of deucrictibant in hereditary angioedema (HAE), sponsored by Pharvaris. Primary endpoint: Effect of multiple doses of PHA-022121 on single-dose pharmacokinetics of CYP probe cocktail. Started Dec 2020; status: active, not recruiting.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NL-OMON49587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49587.